NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...
This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths to improve access to obesity treatment for individuals living with ...
Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...
26mon MSN
Health Care Roundup: Market Talk
Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback